Navigation Links
Medarex Announces 2008 Fourth Quarter and Year End Financial Results
Date:2/25/2009

A regulatory filing for market approval in the U.S. has also been submitted.
  • Announcing the receipt of other milestone payments from licensing partners, NovoNordisk and Pfizer, Inc., for the submission of two separate investigational new drug (IND) filings to the U.S. Food and Drug Administration (FDA) in March 2008 and September 2008, respectively.
  • Reaching strong proof-of-concept Phase 2 data in November 2008 for the C. difficile program (MDX-066 and MDX-1388), which demonstrated a 70 percent reduction in disease recurrence when added to standard of care antibiotics as compared to placebo treatment.
  • Advancing our pipeline with the initiation of Phase 2 trials for the MDX-1100 anti-IP10 antibody for the treatment of ulcerative colitis and rheumatoid arthritis, announced in May 2008, and a Phase 2 trial for the MEDI-545 anti-interferon-alpha antibody being developed by MedImmune Inc., announced in August 2008.
  • Advancing our pipeline with the initiation of Phase 1 oncology trials for the MDX-1411 anti-CD70 antibody for the treatment of renal cancer and lymphoma and a Phase 1b trial for the MDX-1106 anti-PD-1 antibody for the treatment of solid tumors in April 2008 and November 2008, respectively.
  • Expanding our oncology pipeline with two new IND filings with the FDA, one for the MDX-1105 anti-PD-L1 antibody and one for the MDX-1203 anti-CD70 program, Medarex's first antibody-drug conjugate, in August 2008 and December 2008, respectively.
  • Strengthening our cash resources in February 2008 with the addition of approximately $151.8 million through the sale of 2.5 million shares of Genmab A/S common stock, reducing our ownership in Genmab to approximately 5.1 percent.
  • Non-GAAP Financial Measurements

    This press release and the accompanying tables include non-GAAP financial measures. Please see the section of the accompanying
    '/>"/>

    SOURCE Medarex, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine news :

    1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
    2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
    3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
    4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
    5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
    6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
    7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
    8. Medarex Announces 2008 First Quarter Financial Results
    9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
    10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
    11. Medarex Reviews Recent Highlights and Outlook for 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... July 25, 2014 Voted one of ... the global clients, BellasDress focuses on providing its new ... fashion information. Recently, the company has announced its new ... the new range is created according to the latest ... discounts, up to 68% off. , As a matter ...
    (Date:7/24/2014)... 2014 The report, “Content Delivery ... market into various sub-segments with an in-depth analysis ... drivers and restraints for this market with insights ... market data tables and 36 figures spread through ... Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
    (Date:7/24/2014)... Just as fitness and health professionals ... own financial and marketing strength to be important as ... the next level by using the most powerful communication ... Broadcast, Call Tracking and SMS texting solutions . ... messages are quickly become integral in marketing and communication ...
    (Date:7/24/2014)... its 2014 Power of A Award winners, including two ... , The ASA Global Humanitarian Outreach (GHO) program ... the top honors from ASAE. GHO was honored for ... on the global anesthesia crisis and supporting low income ... honored with a Power of A Silver Award for ...
    (Date:7/24/2014)... appears to increase the risk for head and neck cancer ... with DM, but the risk of HNC in patients with ... cancer is the sixth most common type of cancer. It ... an estimated 650,000 new cancer cases and 350,000 cancer deaths ... Insurance Research Database to examine the risk of HNC in ...
    Breaking Medicine News(10 mins):Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3
    ... sites nationwide, - Triples network bandwidth to more than 1 Gbps at ... ... solution, ROCHESTER, N.Y., March 18 Time Warner Telecom,Inc. (Nasdaq: ... businesses, today announced a multi-year, contract,to deploy an eight-site IP VPN solution ...
    ... PartsSource, the nation,s,leading supplier of replacement medical repair ... Team NEO award. Team NEO recognizes,the exceptional companies ... as the engines fueling the Cleveland area economy., ... what,s right about Northern Ohio,business," said President & ...
    ... Using data from the SCIAMACHY instrument aboard ESA,s Envisat ... regionally elevated atmospheric carbon dioxide the most important ... from manmade emissions. , More than 30 billion tonnes ... into the atmosphere annually by human activities, mainly through ...
    ... New U of T research holds promise for ... serve as a model for future therapies against the ... Stagljar, University of Toronto scientists have identified several compounds ... ExoS). One of these compounds, exosin, significantly inhibited infections ...
    ... March 18 On The Go,Healthcare, Inc. (OTC ... computer hardware, software and systems integrator,announced today that ... the Company has sold its Value Added Reseller ... (OTC Bulletin Board: FLIP). The,terms of the sale, ...
    ... or not relatives talk about the familys history of ... and testing for those at moderate risk of developing ... today at the American Society for Preventive Oncology meeting ... African Americans participate less often in genetic counseling and ...
    Cached Medicine News:Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 2Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 3Health News:Envisat makes first ever observation of regionally elevated CO2 from manmade emissions 2Health News:Envisat makes first ever observation of regionally elevated CO2 from manmade emissions 3Health News:Research promising for cystic fibrosis 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 3Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 4Health News:Family communication impacts attitude about genetic counseling/testing for breast cancer 2
    (Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
    (Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 /PRNewswire/ ... that it will release its second quarter 2014 financial ... 31, 2014. In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
    (Date:7/24/2014)... and MENLO PARK, Calif. , July 24, ... ("DelMar" "the company") announced today that the company,s board of ... December 31 to June 30. Accordingly, DelMar will file a ... Jeffrey Bacha , president and CEO of DelMar ... step in achieving our goal of obtaining a senior exchange ...
    Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
    ... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... at the Wedbush Life Sciences Conference in New York on ... Interested parties may access a live audio webcast of the ... www.BMRN.com .  A replay of the call will be ...
    ... Merck,s Schering-Plough unit current and former pharmaceutical representatives ... opinion issued by a Federal Court in Connecticut. ... The law firms of Joseph, Herzfeld, Hester ... represent the plaintiffs in a Nationwide Collective Law Suit. ...
    Cached Medicine Technology:BioMarin to Present at the Wedbush Life Sciences Conference 2UPDATE: Total Victory for Schering-Plough (Now Merck) Pharmaceutical Reps in National Suit for Overtime Pay 2
    The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures....
    ... Webster is the source for a complete ... catheters for left-sided mapping - all with ... come to expect from the leader in ... sinus diagnostic catheters are specifically designed and ...
    ... Inquiry 5FR Soft HIS diagnostic ... a uniquely designed curve that ... in the HIS bundle. In ... designed to reduce the risk ...
    Standard Deflectable Catheters...
    Medicine Products: